Drug Combination Details
| General Information of the Combination (ID: C88284) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | Lonidamine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute myeloid leukemia
[ICD-11: 2A60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BID | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | S6K1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
| In-vitro Model | HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | ||
| U-937 | CVCL_0007 | Adult acute monocytic leukemia | Homo sapiens | |||
| NB4 | CVCL_0005 | Acute promyelocytic leukemia | Homo sapiens | |||
| RPMI-8866 | CVCL_1668 | Chronic myelogenous leukemia | Homo sapiens | |||
| Experimental
Result(s) |
lonidamine efficaciously cooperates with the anti-leukemic agent arsenic trioxide (ATO) to induce apoptosis in HL-60 and other human leukemia cell lines, with low toxicity in non-tumor peripheral blood lymphocytes. | |||||
